Bioventus Inc stated in a filing with the SEC that expected adjustments to reimbursement policies related to the Exogen bone healing system are not anticipated to have a material impact on the company’s financial position for fiscal year 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bearish to 159! Ahead of Friday's Bank of Japan decision, Wall Street strategists collectively bet on a weaker yen
The swap market has fully priced in expectations of a Bank of Japan rate hike. Strategists warn that if the central bank's hawkish stance falls short of estimates, it could trigger a sell-off in the yen, with the exchange rate potentially dipping towards the 159 level in the short term.
Iran’s IRGC claims attack on Togolese oil tanker for 'illegal transit' in Strait of Hormuz
RBA's Bullock: At August board meeting, risks to outlook were skewed to the upside
Lucid (LCID.US) stock price surged over 12%! CEO announces completion of restructuring advisor collaboration, roadmap to profitability emerges
The CEO of Lucid Group Inc. stated that the electric vehicle manufacturer has completed its collaboration with a restructuring advisory team, indicating that the troubled company now has a clearer path to turn around its operations.
Crypto prices
More
